You are here

gene therapy

New York biotech snaps up Eli Lilly neuro veteran as CSO

New York biotech snaps up Eli Lilly neuro veteran as CSO

Fierce Biotech

Redpin Therapeutics

Flag link:

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

BioCentury

Selectra Biosciences

Flag link:

Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy

Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy

Forbes

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

[video+transcript]Gene Therapy Could Be a Boon for This Biotech

[video+transcript]Gene Therapy Could Be a Boon for This Biotech

Motley Fool

spinal muscular atrophy

wet age-related macular degeneration

Flag link:

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

clinical trials

Flag link:

Spark/Novartis eye gene therapy nears EU market – but at what price?

Spark/Novartis eye gene therapy nears EU market – but at what price?

Pharmaforum

Spark Therapeutics

Flag link:

Amicus Therapeutics Ramps Up Gene Therapy Portfolio with Acquisition of 10 Programs

Amicus Therapeutics Ramps Up Gene Therapy Portfolio with Acquisition of 10 Programs

CP Wire

Amicus Therapeutics

Flag link:

Mustang licenses immunodeficiency gene therapy from St. Jude

Mustang licenses immunodeficiency gene therapy from St. Jude

BioCentury

St Jude Children's Hospital

Flag link:

Sarepta Invests $30 Million in Gene Therapy Company

Sarepta Invests $30 Million in Gene Therapy Company

CP Wire

Lacerta Therapeutics

Sarepta Therapeutics

Flag link:

RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study

RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study

Endpoints

clinical trials

Flag link:

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Forbes

Flag link:

Boehringer Ingelheim lands option on cystic fibrosis gene therapy

Boehringer Ingelheim lands option on cystic fibrosis gene therapy

Fierce Biotech

Boehringer Ingelheim

cystic fibrosis

Oxford BioMedica

Flag link:

Bluebird’s first gene therapy gets European fast track

Bluebird’s first gene therapy gets European fast track

PM Live

Flag link:

FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results

FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

Endpoints

PTC Therapeutics

Flag link:

Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Zacks.com

fidanacogene elaparvovec

Flag link:

FDA Releases Six New Draft Guidances on Gene Therapy

FDA Releases Six New Draft Guidances on Gene Therapy

CP Wire

Flag link:

FDA Releases Six New Draft Guidances on Gene Therapy

Flag link:

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Endpoints

Axovant Sciences

Flag link:

Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

Motley Fool

beta thalassemia

Flag link:

Pages